Danesis Perez, APRN
Nurse Practitioner · Tampa, FLNPI 1770036873
Payments from drug & device makers
Across 612 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Inspire Medical Systems, Inc.$2K
- Sanofi$2K
- Boehringer Ingelheim$986
- Takeda Pharmaceuticals U.S.A., Inc.$588
- plus $3K from 28 others
What the payments were for
- Travel & lodging$7885%
- Food & beverage$14,67194%
- Education$941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 205 | $3,710 |
| AstraZeneca | 134 | $3,387 |
| Inspire Medical Systems, Inc. | 16 | $1,780 |
| Sanofi | 36 | $1,625 |
| Boehringer Ingelheim | 37 | $986 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $588 |
| Amgen | 26 | $422 |
| Regeneron Healthcare Solutions, Inc. | 14 | $342 |
| Harmony Biosciences LLC | 10 | $327 |
| Actelion Pharmaceuticals US, Inc. | 7 | $316 |
| Verona Pharma, Inc. | 21 | $283 |
| Jazz Pharmaceuticals Inc. | 10 | $262 |
| Philips North America LLC | 7 | $203 |
| United Therapeutics Corporation | 8 | $189 |
| Pfizer | 6 | $132 |
| Electromed, Inc. | 9 | $113 |
| Novartis | 4 | $112 |
| Intuitive Surgical | 1 | $98 |
| Paratek Pharmaceuticals, Inc. | 5 | $93 |
| Johnson & Johnson | 4 | $85 |
| Insmed, Inc. | 3 | $79 |
| Lilly USA, LLC | 3 | $64 |
| Itamar Medical Inc | 1 | $62 |
| Mallinckrodt Hospital Products Inc. | 2 | $45 |
| Baxter Healthcare | 2 | $40 |
| Inogen, Inc. | 2 | $35 |
| Merck | 1 | $31 |
| Sanofi US Services Inc. | 1 | $31 |
| Covis Pharma GmbH | 1 | $29 |
| Grifols USA, LLC | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| Optinose US, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,554 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 196 | $165,894 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $89,648 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 95 | $48,187 |
| Spiriva RespimatTiotropium Bromide | 63 | $47,571 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 57 | $38,462 |
| EliquisApixaban | 30 | $30,741 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $26,502 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $19,197 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $12,165 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 321 | $9,005 |
| Roflumilast | 29 | $4,870 |
| Arnuity ElliptaFluticasone Furoate | 16 | $4,371 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $2,467 |
| Ventolin HfaAlbuterol Sulfate | 35 | $2,215 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $2,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $3,710 | $257,120380 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,387 | $108,845153 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $986 | $86,033120 claims |
| PfizerEliquis | $132 | $30,74130 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Tampa
- April WessonTampa$342K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Jennifer PuleoTampa$171K
- Melissa CarverTampa$129K
- Jerrica FariasTampa$127K
- Sara TinsleyTampa$93K
- Erin ParkinsonTampa$65K
- Michele LaineTampa$58K
- Jana BucknerTampa$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.